TY - JOUR
T1 - A novel ABCC6 haplotype is associated with azathioprine drug response in myasthenia gravis
AU - Colleoni, Lara
AU - Galbardi, Barbara
AU - Barzago, Claudia
AU - Bonanno, Silvia
AU - Franzi, Sara
AU - Frangiamore, Rita
AU - Camera, Giorgia
AU - Foti, Maria
AU - Biancolini, Donatella
AU - Canioni, Eleonora
AU - Maggi, Lorenzo
AU - Antozzi, Carlo
AU - Mantegazza, Renato
AU - Bernasconi, Pia
AU - Kapetis, Dimos
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Objective We investigated the association of single nucleotide polymorphisms (SNPs) in drug-metabolizing enzymes and transporters (DMETs) with the response to azathioprine (AZA) in patients affected by myasthenia gravis (MG) to determine possible genotype-phenotype correlations. Patients and methods Genomic DNA from 180 AZA-treated MG patients was screened through the Affymetrix DMET platform, which characterizes 1931 SNPs in 225 genes. The significant SNPs, identified to be involved in AZA response, were subsequently validated by allelic discrimination and direct sequencing. SNP analysis was carried out using the SNPassoc R package and the haploblocks were determined using haploview software. Results We studied 127 patients in the discovery phase and 53 patients in the validation phase. We showed that two SNPs (rs8058694 and rs8058696) found in ATP-binding cassette subfamily C member 6, a subfamily member of ATP-binding cassette genes, constituted a new haplotype associated with AZA response in MG patients in the discovery cohort (P =0.011; odds ratio: 0.40; 95% confidence interval: 0.20-0.83) and in the combined cohort (P= 0.04; odds ratio: 1.58). Conclusion These findings highlight the role that the ATP-binding cassette subfamily C member 6 haplotype may play in AZA drug response. In view of the significant effects and AZA intolerance, these novel SNPs should be taken into consideration in pharmacogenetic profiling for AZA.
AB - Objective We investigated the association of single nucleotide polymorphisms (SNPs) in drug-metabolizing enzymes and transporters (DMETs) with the response to azathioprine (AZA) in patients affected by myasthenia gravis (MG) to determine possible genotype-phenotype correlations. Patients and methods Genomic DNA from 180 AZA-treated MG patients was screened through the Affymetrix DMET platform, which characterizes 1931 SNPs in 225 genes. The significant SNPs, identified to be involved in AZA response, were subsequently validated by allelic discrimination and direct sequencing. SNP analysis was carried out using the SNPassoc R package and the haploblocks were determined using haploview software. Results We studied 127 patients in the discovery phase and 53 patients in the validation phase. We showed that two SNPs (rs8058694 and rs8058696) found in ATP-binding cassette subfamily C member 6, a subfamily member of ATP-binding cassette genes, constituted a new haplotype associated with AZA response in MG patients in the discovery cohort (P =0.011; odds ratio: 0.40; 95% confidence interval: 0.20-0.83) and in the combined cohort (P= 0.04; odds ratio: 1.58). Conclusion These findings highlight the role that the ATP-binding cassette subfamily C member 6 haplotype may play in AZA drug response. In view of the significant effects and AZA intolerance, these novel SNPs should be taken into consideration in pharmacogenetic profiling for AZA.
KW - Azathioprine
KW - Drug response
KW - Drug-metabolizing enzymes and transport
KW - Myasthenia gravis
UR - http://www.scopus.com/inward/record.url?scp=85002157006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002157006&partnerID=8YFLogxK
U2 - 10.1097/FPC.0000000000000257
DO - 10.1097/FPC.0000000000000257
M3 - Article
C2 - 27922550
AN - SCOPUS:85002157006
VL - 27
SP - 51
EP - 56
JO - Pharmacogenetics and Genomics
JF - Pharmacogenetics and Genomics
SN - 1744-6872
IS - 2
ER -